Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

Toxicon

Volumn 59, Issue 4, 2012, Pages 529-546

  Chi, Victor ^a   Pennington, Michael W ^b   Norton, Raymond S ^c   Tarcha, Eric J ^d   Londono, Luz M ^d   Sims Fahey, Brian ^d   Upadhyay, Sanjeev K ^a   Lakey, Jonathan T ^a   Iadonato, Shawn ^d   Wulff, Heike ^e   Beeton, Christine ^f   Chandy, K George ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Peptides International   (United States)

^c MONASH UNIVERSITY   (Australia)

^d Kineta Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune; B cell; BgK; CRAC; KCa3.1; Kv1.3; Multiple sclerosis; PAP 1; Potassium channel; Psoriasis; Rheumatoid arthritis; Sea anemone; ShK; ShK 186; ShK 192; T cell; Toxin; Transplant; Type 1 diabetes mellitus

Indexed keywords

CALCIUM; CD27 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CLOFAZIMINE; CYCLOSPORIN A; IMMUNOGLOBULIN D; PAP 1; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KV1.3; PRISTANE; SEA ANEMONE TOXIN; SHK; SHK 168; SHK 170; SHK 186; SHK 192; SHK Q16K; TRAM 34; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC GLOMERULONEPHRITIS; ARTHRITIS; AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET TRANSPLANTATION; PHARMACODYNAMICS; POTASSIUM CURRENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEA ANEMONE; SKIN DISCOLORATION; SKIN TRANSPLANTATION; STICHODACTYLA HELIANTHUS; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CNIDARIAN VENOMS; DRUG TOXICITY; IMMUNOLOGIC FACTORS; ION CHANNELS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEA ANEMONES;

ACTINIARIA; STICHODACTYLA HELIANTHUS;

EID: 84857039386     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.07.016     Document Type: Review

References (91)

1. Agematsu K., Hokibara S., Nagumo H., Komiyama A. CD27: a memory B-cell marker. Immunol. Today 2000, 21:204-206.
2. Azam P., Sankaranarayanan A., Homerick D., Griffey S., Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 2007, 127:1419-1429.
3. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 2005, 67:1369-1381.
4. + channels and inhibits T lymphocyte proliferation. J. Biol. Chem. 2008, 283:988-997.
5. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13942-13947.
6. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., Leehealey C.J., Andrews B.S., Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.G., Nepom G.T., Gutman G.A., Calabresi P.A., Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17414-17419.
7. Boswell C.A., Tesar D.B., Mukhyala K., Theil F.P., Fielder P.J., Khawli L.A. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug. Chem. 2010, 21:2153-2163.
8. Cahalan M.D., Chandy K.G. The functional network of ion channels in T lymphocytes. Immunol. Rev. 2009, 231:59-87.
9. Castaneda O., Harvey A.L. Discovery and characterization of Cnidarian peptide toxins that affect neuronal potassium ion channels. Toxicon 2009, 54:1119-1124.
10. Castaneda O., Sotolongo V., Amor A.M., Stocklin R., Anderson A.J., Harvey A.L., Engstrom A., Wernstedt C., Karlsson E. Characterization of a potassium channel toxin from the Caribbean sea anemone Stichodactyla helianthus. Toxicon 1995, 33:603-613.
11. Chandy K.G., Wulff H., Beeton C., Pennington M., Gutman G.A., Cahalan M.D. Potassium channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 2004, 25:280-289.
12. Chuaprapaisilp T., Piamphongsant T. Treatment of pustular psoriasis with clofazimine. Br. J. Dermatol. 1978, 99:303-305.
13. Clark R.A. Skin-resident T cells: the ups and downs of on site immunity. J. Invest. Dermatol. 2010, 130:362-370.
14. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11064-11069.
15. Cotton J., Crest M., Bouet F., Alessandri N., Gola M., Forest E., Karlsson E., Castaneda O., Harvey A., Vita C., Menez A. A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity. Eur. J. Biochem. 1997, 244:192-202.
16. Craythorn J.M., Swartz M., Creel D.J. Clofazimine-induced bull's-eye retinopathy. Retina 1986, 6:50-52.
17. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 2010, 1183:211-221.
18. + channels in human T lymphocytes: a role in mitogenesis?. Nature 1984, 307:465-468.
19. high plasma cells and disease activity in systemic lupus erythematosus. Lupus 2004, 13:283-289.
20. + T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand. J. Immunol. 2004, 60:199-208.
21. Fordyce C.B., Jagasia R., Zhu X., Schlichter L.C. Microglia Kv1.3 channels contribute to their ability to kill neurons. J. Neurosci. 2005, 25:7139-7149.
22. Friedrich M., Krammig S., Henze M., Docke W.D., Sterry W., Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory effector/type 1 immunophenotype. Arch. Dermatol. Res. 2000, 292:519-521.
23. Gendeh G.S., Chung M.C., Jeyaseelan K. Genomic structure of a potassium channel toxin from Heteractis magnifica. FEBS Lett. 1997, 418:183-188.
24. Gendeh G.S., Young L.C., de Medeiros C.L., Jeyaseelan K., Harvey A.L., Chung M.C. A new potassium channel toxin from the sea anemone Heteractis magnifica: isolation, cDNA cloning, and functional expression. Biochemistry 1997, 36:11461-11471.
25. Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A., Cahalan M.D., Chandy K.G. Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J. Biol. Chem. 2000, 275:37137-37149.
26. Gilhar A., Bergman R., Assay B., Ullmann Y., Etzioni A. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J. Invest. Dermatol. 2011, 131:118-124.
27. Grgic I., Wulff H., Eichler I., Flothmann C., Kohler R., Hoyer J. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant. Proc. 2009, 41:2601-2606.
28. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., Burmester G.R., Lipsky P.E., Dorner T. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2002, 46:2160-2171.
29. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., Sack U. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun. Rev. 2011, 9:785-792.
30. Honma T., Kawahata S., Ishida M., Nagai H., Nagashima Y., Shiomi K. Novel peptide toxins from the sea anemone Stichodactyla haddoni. Peptides 2008, 29:536-544.
31. Hultqvist M., Olofsson P., Gelderman K.A., Holmberg J., Holmdahl R. A new arthritis therapy with oxidative burst inducers. PLoS Med. 2006, 3:e348.
32. Hyodo T., Oda T., Kikuchi Y., Higashi K., Kushiyama T., Yamamoto K., Yamada M., Suzuki S., Hokari R., Kinoshita M., Seki S., Fujinaka H., Yamamoto T., Miura S., Kumagai H. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am. J. Physiol. Ren. Physiol. 2010, 299:F1258-F1269.
33. high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003, 48:1332-1342.
34. Kalman K., Pennington M.W., Lanigan M.D., Nguyen A., Rauer H., Mahnir V., Paschetto K., Kem W.R., Grissmer S., Gutman G.A., Christian E.P., Cahalan M.D., Norton R.S., Chandy K.G. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 1998, 273:32697-32707.
35. + channels and the microglial respiratory burst. Am. J. Physiol. Cell Physiol. 2001, 280:C796-C806.
36. Koo G.C., Blake J.T., Shah K., Staruch M.J., Dumont F., Wunderler D., Sanchez M., McManus O.B., Sirotina-Meisher A., Fischer P., Boltz R.C., Goetz M.A., Baker R., Bao J., Kayser F., Rupprecht K.M., Parsons W.H., Tong X.C., Ita I.E., Pivnichny J., Vincent S., Cunningham P., Hora D., Feeney W., Kaczorowski G., et al. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell. Immunol. 1999, 197:99-107.
37. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., Shah K., Mulvany K., Hora D., Cunningham P., Wunderler D.L., McManus O.B., Slaughter R., Bugianesi R., Felix J., Garcia M., Williamson J., Kaczorowski G., Sigal N.H., Springer M.S., Feeney W. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 1997, 158:5120-5128.
38. Lanigan M.D., Kalman K., Lefievre Y., Pennington M.W., Chandy K.G., Norton R.S. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry 2002, 41:11963-11971.
39. Lee S.J., Wegner S.A., McGarigle C.J., Bierer B.E., Antin J.H. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997, 89:2298-2302.
40. + memory B cells in blood of patients with autoimmune thyroid disease. Eur. J. Immunol. 2002, 32:3126-3132.
41. 2+-dependent mechanism. Am. J. Physiol. Cell Physiol. 2006, 290:C345-C351.
42. Lioudyno M.I., Kozak J.A., Penna A., Safrina O., Zhang S.L., Sen D., Roos J., Stauderman K.A., Cahalan M.D. Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2011-2016.
43. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: a marker of activated/memory T cells. J. Clin. Invest. 1998, 101:725-730.
44. Luik R.M., Wang B., Prakriya M., Wu M.M., Lewis R.S. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature 2008, 454:538-542.
45. Mathelier-Fusade P. Drug-induced urticarias. Clin. Rev. Allergy Immunol. 2006, 30:19-23.
46. Matheu M.P., Beeton C., Garcia A., Chi V., Rangaraju S., Safrina O., Monaghan K., Uemura M.I., Li D., Pal S., de la Maza L.M., Monuki E., Flugel A., Pennington M.W., Parker I., Chandy K.G., Cahalan M.D. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008, 29:602-614.
47. Mathew B.S., Pulimood A.B., Prasanna C.G., Ramakrishna B.S., Chandy S.J. Clofazimine induced enteropathy - a case highlighting the importance of drug induced disease in differential diagnosis. Trop. Gastroenterol. 2006, 27:87-88.
48. Matteson D.R., Deutsch C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 1984, 307:468-471.
49. McDougall A.C., Horsfall W.R., Hede J.E., Chaplin A.J. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. Br. J. Dermatol. 1980, 102:227-230.
50. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009, 361:888-898.
51. - T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis. Mult. Scler. 2008, 14:1044-1055.
52. + channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem. J. 2005, 385:95-104.
53. Mullen K.M., Rozycka M., Rus H., Hu L., Cudrici C., Zafranskaia E., Pennington M.W., Johns D.C., Judge S.I., Calabresi P.A. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann. Neurol. 2006, 60:118-127.
54. Nagumo H., Agematsu K., Kobayashi N., Shinozaki K., Hokibara S., Nagase H., Takamoto M., Yasui K., Sugane K., Komiyama A. The different process of class switching and somatic hypermutation; a novel analysis by CD27(-) naive B cells. Blood 2002, 99:567-575.
55. Nair L.V., Shereef P.H. Successful treatment of generalized pustular psoriasis with clofazimine. Int. J. Dermatol. 1991, 30:151.
56. + channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. Am. J. Physiol. Cell Physiol. 2007, 292:C1431-C1439.
57. Norton R.S., Pennington M.W., Wulff H. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr. Med. Chem. 2004, 11:3041-3052.
58. Omar B.A., Flores S.C., McCord J.M. Superoxide dismutase: pharmacological developments and applications. Adv. Pharmacol. 1992, 23:109-161.
59. Panyi G., Vamosi G., Bacso Z., Bagdany M., Bodnar A., Varga Z., Gaspar R., Matyus L., Damjanovich S. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1285-1290.
60. Parizhskaya M., Youssef N.N., Di Lorenzo C., Goyal R.K. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. J. Pediatr. 2001, 138:574-576.
61. Park C.Y., Hoover P.J., Mullins F.M., Bachhawat P., Covington E.D., Raunser S., Walz T., Garcia K.C., Dolmetsch R.E., Lewis R.S. STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1. Cell 2009, 136:876-890.
62. Penna A., Demuro A., Yeromin A.V., Zhang S.L., Safrina O., Parker I., Cahalan M.D. The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature 2008, 456:116-120.
63. Pennington M.W., Byrnes M., Zaydenberg I., Khaytin I., de Chastonay J., Krafte D., Hill R., Mahnir V., Volberg W., Gorczyca W., Kem W.R. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res. 1995, 346:354-358.
64. Pennigton M.W., Lanigan M.D., Mahnir V., Rauer H., McVaugh C.T., Behm D., Donaldson D., Chandy K.G., Kem W.R., Norton R.S. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin. Biochemistry 1999, 38:14549-14558.
65. Pennington M.W., Mahnir V., Khaytin I., Zaydenberg I., Byrnes M., Kem W.R. An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 1996, 35:16407-16411.
66. Pennington M.W., Beeton C., Galea C.A., Smith B.J., Chi V., Monaghan K.P., Garcia A., Rangaraju S., Giuffrida A., Plank D., Crossley G., Nugent D., Khaytin I., Lefievre Y., Peshenko I., Dixon C., Chauhan S., Orzel A., Inoue T., Hu X., Moore R.V., Norton R.S., Chandy K.G. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol. Pharmacol. 2009, 75:762-773.
67. Pereira L.E., Villinger F., Wulff H., Sankaranarayanan A., Raman G., Ansari A.A. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp. Biol. Med. (Maywood) 2007, 232:1338-1354.
68. Pohl J., Hubalek F., Byrnes M.E., Nielsen K.R., Woods A., Pennington M.W. Assignment of the three disulfide bonds in ShK toxin: a potent potassium channel inhibitor from the sea anemone Stichodactyla helianthus. Lett. Pept. Sci. 1995, 1:291-297.
69. Rauer H., Pennington M., Cahalan M., Chandy K.G. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem. 1999, 274:21885-21892.
70. Ren Y.R., Pan F., Parvez S., Fleig A., Chong C.R., Xu J., Dang Y., Zhang J., Jiang H., Penner R., Liu J.O. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE 2008, 3:e4009.
71. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., Niculescu F., Mullen K.M., Allie R., Guo L., Wulff H., Beeton C., Judge S.I., Kerr D.A., Knaus H.G., Chandy K.G., Calabresi P.A. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11094-11099.
72. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
73. Schlichter L., Sidell N., Hagiwara S. Potassium channels mediate killing by human natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:451-455.
74. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hansel W., Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 2005, 68:1254-1270.
75. Shiomi K. Novel peptide toxins recently isolated from sea anemones. Toxicon 2009, 54:1112-1118.
76. Sidell N., Schlichter L.C., Wright S.C., Hagiwara S., Golub S.H. Potassium channels in human NK cells are involved in discrete stages of the killing process. J. Immunol. 1986, 137:1650-1658.
77. Straub S.V., Perez S.M., Tan B., Coughlan K.A., Trebino C.E., Cosgrove P., Buxton J.M., Kreeger J.M., Jackson V.M. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. Am. J. Physiol. Endocrinol. Metab. 2011, (Epub date 2011/05/19).
78. Sullivan J.K., Miranda L.P., Gegg C.V., Hu S., Belouski E.J., Murray J.K., Nguyen H., Walker K.W., Arora T., Jacobsen F.W., Li Y., Boone T.C. Selective and Potent Peptide Inhibitors of Kv1.3 2010, WO 2010/108154A2, Amgen, p. 288.
79. Tucker K., Overton J.M., Fadool D.A. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. Int. J. Obes. (Lond.) 2008, 32:1222-1232.
80. Tudor J.E., Pallaghy P.K., Pennington M.W., Norton R.S. Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat. Struct. Biol. 1996, 3:317-320.
81. Tudor J.E., Pennington M.W., Norton R.S. Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin. Eur. J. Biochem. 1998, 251:133-141.
82. Vennekamp J., Wulff H., Beeton C., Calabresi P.A., Grissmer S., Hansel W., Chandy K.G. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol. Pharmacol. 2004, 65:1364-1374.
83. Viglietta V., Kent S.C., Orban T., Hafler D.A. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 2002, 109:895-903.
84. +) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 2004, 150:852-859.
85. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111:1703-1713.
86. + channel expression during B-cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 2004, 173:776-786.
87. Wulff H., Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Devel. 2007, 10:438-445.
88. Xu J., Koni P.A., Wang P., Li G., Kaczmarek L., Wu Y., Li Y., Flavell R.A., Desir G.V. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum. Mol. Genet. 2003, 12:551-559.
89. Xu J., Wang P., Li Y., Li G., Kaczmarek L.K., Wu Y., Koni P.A., Flavell R.A., Desir G.V. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3112-3117.
90. Yamaguchi Y., Hasegawa Y., Honma T., Nagashima Y., Shiomi K. Screening and cDNA cloning of Kv1 potassium channel toxins in sea anemones. Mar. Drugs 2011, 8:2893-2905.
91. Zsiros E., Kis-Toth K., Hajdu P., Gaspar R., Bielanska J., Felipe A., Rajnavolgyi E., Panyi G. Developmental switch of the expression of ion channels in human dendritic cells. J. Immunol. 2009, 183:4483-4492.